Castle Biosciences (CSTL) News Today $20.84 -0.14 (-0.67%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$20.85 +0.01 (+0.05%) As of 03/25/2025 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Castle Biosciences, Inc. (NASDAQ:CSTL) Position Trimmed by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. trimmed its holdings in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 5.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 258,866 shares of the company's stock after seMarch 24 at 3:13 AM | marketbeat.comCastle Biosciences management to meet with StephensMarch 21, 2025 | markets.businessinsider.comBrokerages Set Castle Biosciences, Inc. (NASDAQ:CSTL) Target Price at $40.00March 16, 2025 | americanbankingnews.comCastle Biosciences, Inc. (NASDAQ:CSTL) Given Consensus Recommendation of "Buy" by AnalystsCastle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) has received a consensus rating of "Buy" from the seven ratings firms that are covering the stock, Marketbeat reports. Seven research analysts have rated the stock with a buy rating. The average 1-year price objective among analysts that havMarch 13, 2025 | marketbeat.comDerek J. Maetzold Sells 2,130 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) StockCastle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek J. Maetzold sold 2,130 shares of the business's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $19.52, for a total value of $41,577.60. Following the completion of the transaction, the insider now owns 78,335 shares in the company, valued at $1,529,099.20. The trade was a 2.65 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.March 12, 2025 | marketbeat.comCastle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells $455,496.68 in StockCastle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek J. Maetzold sold 22,639 shares of the stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $20.12, for a total transaction of $455,496.68. Following the sale, the insider now directly owns 80,465 shares in the company, valued at $1,618,955.80. This represents a 21.96 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.March 12, 2025 | marketbeat.comInsider Selling: Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells 2,130 Shares of StockMarch 12, 2025 | insidertrades.comLisanti Capital Growth LLC Cuts Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL)Lisanti Capital Growth LLC lessened its stake in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 70.1% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 46,265 shares of the company's stock after selling 108,445 shares during the quarter. Lisanti Capital GMarch 8, 2025 | marketbeat.comCastle Biosciences (NASDAQ:CSTL) Shares Down 3.8% - Should You Sell?Castle Biosciences (NASDAQ:CSTL) Shares Down 3.8% - Here's What HappenedMarch 6, 2025 | marketbeat.comSolid Earnings Reflect Castle Biosciences' (NASDAQ:CSTL) Strength As A BusinessMarch 6, 2025 | finance.yahoo.comCastle Biosciences (CSTL) Gets a Buy from ScotiabankMarch 4, 2025 | markets.businessinsider.comLeerink Partnrs Weighs in on CSTL Q1 EarningsCastle Biosciences, Inc. (NASDAQ:CSTL - Free Report) - Stock analysts at Leerink Partnrs issued their Q1 2026 EPS estimates for Castle Biosciences in a research report issued to clients and investors on Friday, February 28th. Leerink Partnrs analyst P. Souda expects that the company will earn ($0March 3, 2025 | marketbeat.comCastle Biosciences (NASDAQ:CSTL) Shares Gap Up Following Analyst UpgradeCastle Biosciences (NASDAQ:CSTL) Shares Gap Up Following Analyst UpgradeMarch 1, 2025 | marketbeat.comCastle Biosciences (NASDAQ:CSTL) Given New $37.00 Price Target at Robert W. BairdRobert W. Baird lifted their price objective on shares of Castle Biosciences from $36.00 to $37.00 and gave the stock an "outperform" rating in a report on Friday.March 1, 2025 | marketbeat.comCastle Biosciences (NASDAQ:CSTL) Posts Quarterly Earnings Results, Beats Expectations By $0.36 EPSCastle Biosciences (NASDAQ:CSTL - Get Free Report) posted its earnings results on Thursday. The company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.36. Castle Biosciences had a return on equity of 1.47% and a net margin of 1.95%.February 28, 2025 | marketbeat.comCastle Biosciences price target raised to $37 from $36 at BairdFebruary 28, 2025 | markets.businessinsider.comCastle Biosciences sees FY25 revenue $280M-$295M, consensus $269.06MFebruary 27, 2025 | markets.businessinsider.comCastle Biosciences, Inc. (CSTL) Q4 2024 Earnings Call TranscriptFebruary 27, 2025 | seekingalpha.comCastle Biosciences, Inc. 2024 Q4 - Results - Earnings Call PresentationFebruary 27, 2025 | seekingalpha.comCastle Biosciences Reports Fourth Quarter and Full-Year 2024 ResultsFebruary 27, 2025 | businesswire.comWhat To Expect From Castle Biosciences Inc (CSTL) Q4 2024 EarningsFebruary 26, 2025 | finance.yahoo.comCastle Biosciences to Participate in Upcoming Investor ConferencesFebruary 25, 2025 | businesswire.comPrincipal Financial Group Inc. Has $38.26 Million Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL)Principal Financial Group Inc. decreased its position in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 6.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,435,665 shares of the company'sFebruary 22, 2025 | marketbeat.com73,500 Shares in Castle Biosciences, Inc. (NASDAQ:CSTL) Purchased by Hussman Strategic Advisors Inc.Hussman Strategic Advisors Inc. bought a new stake in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 73,500 shares of the company's stock, valued at approximately $1,9February 21, 2025 | marketbeat.comCastle Biosciences (CSTL) Expected to Announce Earnings on ThursdayCastle Biosciences (NASDAQ:CSTL) will be releasing earnings after the market closes on Thursday, February 27. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=663251)February 20, 2025 | marketbeat.comKornitzer Capital Management Inc. KS Has $10.23 Million Position in Castle Biosciences, Inc. (NASDAQ:CSTL)Kornitzer Capital Management Inc. KS lessened its position in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 5.7% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 383,974 shares of the company's stock after selling 23,264 shares during the qFebruary 19, 2025 | marketbeat.comCastle Biosciences, Inc. (NASDAQ:CSTL) Receives Consensus Rating of "Buy" from AnalystsShares of Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) have been given a consensus recommendation of "Buy" by the seven brokerages that are currently covering the company, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average tFebruary 16, 2025 | marketbeat.comLegato Capital Management LLC Has $277,000 Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL)Legato Capital Management LLC lessened its stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 60.5% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 10,395 shares of the company's stock after selling 15,890 sharesFebruary 15, 2025 | marketbeat.comCastle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology Conference - Hawaii®February 12, 2025 | businesswire.comCastle Biosciences director sells $221,636 in stockFebruary 7, 2025 | msn.comCastle Biosciences, Inc. (NASDAQ:CSTL) Director Sells $221,613.39 in StockCastle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) Director Daniel Bradbury sold 7,867 shares of the business's stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $28.17, for a total transaction of $221,613.39. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.February 7, 2025 | marketbeat.comTritonpoint Wealth LLC Cuts Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL)Tritonpoint Wealth LLC reduced its stake in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 17.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 46,637 shares of the company's stock after selling 10,000 shares during the periodFebruary 2, 2025 | marketbeat.comStrong week for Castle Biosciences (NASDAQ:CSTL) shareholders doesn't alleviate pain of three-year lossFebruary 1, 2025 | finance.yahoo.comCastle Biosciences: Buy Rating Affirmed Amid Positive Financial Outlook from Novitas Decision DelayJanuary 28, 2025 | markets.businessinsider.comLake Street raises Castle Biosciences 2025 estimates after Novitas delayJanuary 28, 2025 | markets.businessinsider.comLeerink Partnrs Issues Optimistic Estimate for CSTL EarningsCastle Biosciences, Inc. (NASDAQ:CSTL - Free Report) - Equities researchers at Leerink Partnrs upped their Q4 2024 earnings per share (EPS) estimates for Castle Biosciences in a note issued to investors on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now forecasts that the company willJanuary 23, 2025 | marketbeat.comJPMorgan Chase & Co. Has $1.98 Million Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL)JPMorgan Chase & Co. lifted its holdings in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 165.2% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 69,409 shares of the company's stock after purchasing an aJanuary 23, 2025 | marketbeat.comLeerink Partnrs Has Positive Outlook of CSTL FY2024 EarningsCastle Biosciences, Inc. (NASDAQ:CSTL - Free Report) - Analysts at Leerink Partnrs increased their FY2024 earnings estimates for shares of Castle Biosciences in a research report issued to clients and investors on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now anticipates that the coJanuary 22, 2025 | marketbeat.comLeerink Partners Keeps Their Buy Rating on Castle Biosciences (CSTL)January 22, 2025 | markets.businessinsider.comCastle Biosciences, Inc. (NASDAQ:CSTL) Given Consensus Recommendation of "Buy" by BrokeragesShares of Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) have received an average rating of "Buy" from the seven ratings firms that are currently covering the stock, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy rating. The average 1-year priceJanuary 22, 2025 | marketbeat.comCastle Biosciences (NASDAQ:CSTL) Trading 8.1% Higher - Time to Buy?Castle Biosciences (NASDAQ:CSTL) Trading Up 8.1% - Here's What HappenedJanuary 21, 2025 | marketbeat.comCastle Biosciences to share data on DecisionDx-SCCJanuary 17, 2025 | markets.businessinsider.comDerek J. Maetzold Sells 986 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) StockCastle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek J. Maetzold sold 986 shares of the company's stock in a transaction on Monday, January 13th. The stock was sold at an average price of $28.03, for a total transaction of $27,637.58. Following the transaction, the insider now owns 80,818 shares of the company's stock, valued at approximately $2,265,328.54. This represents a 1.21 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.January 15, 2025 | marketbeat.comCastle Biosciences stock tumbles following guidance concernsJanuary 13, 2025 | investing.comCastle Biosciences (NASDAQ:CSTL) Trading Down 14% - Here's WhyCastle Biosciences (NASDAQ:CSTL) Shares Down 14% - Should You Sell?January 13, 2025 | marketbeat.comCastle expects FY24 revenue to meet or exceed top end of $320M-$330M guidanceJanuary 13, 2025 | msn.comCastle Biosciences Positioned for Growth After Novitas Resolution and Focus on Core FranchisesJanuary 13, 2025 | markets.businessinsider.comCastle Biosciences Expects To Meet Or Exceed Top End Of FY24 Revenue GuidanceJanuary 13, 2025 | markets.businessinsider.comBarclays PLC Has $1.49 Million Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL)Barclays PLC increased its stake in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 310.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 52,301 shares of the company's stock after purchasing an additionalJanuary 13, 2025 | marketbeat.comCastle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 ResultsJanuary 12, 2025 | businesswire.com Remove Ads Get Castle Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CSTL and its competitors with MarketBeat's FREE daily newsletter. Email Address CSTL Media Mentions By Week CSTL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CSTL News Sentiment▼1.270.77▲Average Medical News Sentiment CSTL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CSTL Articles This Week▼34▲CSTL Articles Average Week Remove Ads Get Castle Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CSTL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Ardent Health Partners News Progyny News agilon health News PACS Group News Addus HomeCare News Teladoc Health News National HealthCare News AdaptHealth News Viridian Therapeutics News Grail News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CSTL) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredThis Crypto Is Set to Explode in FebruaryBryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Castle Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Castle Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
